MANIFESTATION OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME DURING ANTIRETROVIRAL THERAPY IN PATIENTS WITH HIV INFECTION

  • Authors: KRAVCHENKO A.V1, ZIMINA V.N2, VIKTOROVA I.B3, SITDYKOVA Y.R4
  • Affiliations:
    1. Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Moscow
    2. Central Research Institute of Tuberculosis, Russian Academy of Medical Sciences, Moscow
    3. Novokuznetsk State Institute for Postgraduate Training of Physicians, Ministry of Health and Social Development of Russia
    4. I.A. Sechenov First Moscow State Medical University
  • Issue: No 1 (2011)
  • Pages: 58
  • Section: Articles
  • URL: https://journals.eco-vector.com/2226-6976/article/view/287220
  • ID: 287220

Cite item

Full Text

Abstract

The review analyzes the international experience with clinical observations of the development of various secondary infectious diseases at the start of successful antiretroviral therapy in patients with HIV infection and immune reconstitution inflammatory syndrome (IRIS). It presents the clinical results of studying the pathogenetic components leading to the development of IRIS and its incidence depending on the baseline count of CD4+ lymphocytes; considers clinical and laboratory criteria for tuberculosis-associated IRIS; characterizes the clinical manifestations of the most common secondary diseases developing as a manifestation of IRIS; and discusses the present views of management tactics for this category of patients.

Full Text

Restricted Access

About the authors

A. V KRAVCHENKO

Central Research Institute of Epidemiology, Russian Inspectorate for the Protection of Consumer Rights and Human Welfare, Moscow

Email: kravtchenko@hivrussia.net

V. N ZIMINA

Central Research Institute of Tuberculosis, Russian Academy of Medical Sciences, Moscow

I. B VIKTOROVA

Novokuznetsk State Institute for Postgraduate Training of Physicians, Ministry of Health and Social Development of Russia

Yu. R SITDYKOVA

I.A. Sechenov First Moscow State Medical University

References

  1. Jacobson M.A., Zegans M., Pavan P.R. et al. Cytomegalovirus retinitis after initiation of HAART. Lancet. 1997; 349: 1443-1445.
  2. Race E.M., Adelson-Mitty J., Kriegel G.R. et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet; 1998: 351: 252-255.
  3. French M.A. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin. Infect. Dis. 2009; 48:101-107.
  4. Shelburne S.A., Monies M., Hamill R. J. Immune reconstitution inflammatory syndrome: more answers, more questions. J. Antimicrob. Chemother. 2006; 57(2): 167-170.
  5. Meintjes G., Lawn S.D., ScanoF. etal. Luberculosis-associated immune 5. reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet. Infect. Dis. 2008;8: 516-523.
  6. Foudraine N.A., Hovenkamp E., Notermans D.W. et al. Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 1999; 13(2): 177-184.
  7. Imami N., Antonopoulos C., Hardy G.A. et al. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS. Res. Hum. Retroviruses. 1999 ; 15(17) : 1499-1508.
  8. Stone S.F., Price P., French M.A. Immune restoration disease: a consequence of dysregulated immune responses after HAARL Curr. HIVRes. 2004; 2(3): 235-242.
  9. Grant P.M., Komarow L., Andersen J. et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ARL during an opportunistic infection. PLoS One. 2010; 5(7): ell416.
  10. Samuel A., Shelbume L., Richard J. Lhe immune reconstitution inflammatory syndrome. AIDS Rev. 2003; 5: 67-79.
  11. Stone S.R., Price P., Keane N.M. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAARL. HIV Med. -2002; 3(1): 21-27.
  12. Colebunders R., John L., Huyst V. et al. Luberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int. J. Luberc. Lung Dis. 2006;10(9): 946-953.
  13. Breen R.A., Smith C.J., Cropley I. et al. Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS. 2005; 19(11): 1201-1206.
  14. Lawn S.D., Wilkinson R.J., Lipman M.C. et al. Immune reconstitution and «unmasking» of tuberculosis during antiretroviral therapy. Am. J. Respir. Crit. Care. Med. 2008; 177: 680-685.
  15. Hoffmann C., Degen O., Horst H.A. et al. Immune reconstitution in severely immunocompromised patients initiating HAARL - the critical first months. 7th Deutscher AIDS-Kongress, Essen. 1999; F1088.
  16. Shelburne S.A., Darcourt J., White A.C. et al. Lhe role of immune reconstitution inammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 2005; 40: 1049-1052.
  17. Хоффман К. Лечение ВИЧ-инфекции: Пер. с англ. М.: Р. Валент. 2010.
  18. Manosuthi W., Kiertiburanakul S., Phoorisri T. et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J. Infect.. 2006; 53(6): 357-363.
  19. French M.A., Lenzo N., John M. et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with HAARL. HIV Med. 2000; (1): 107-115.
  20. Ъартлетт Дж. Клинические аспекты ВИЧ-инфекции 2009-2010: Пер. с англ. М.: Р. Валент, 2010.
  21. Serra F.С., Hadad D., Orofino R.L. et al. Immune reconstitution syndrome in patients treated for HIV and tuberculosis in Rio de Janeiro. // Braz. J. Infect. Dis. 2007; 11(5): 462-465.
  22. Rojas C., Solari L., Herrera С. et al. Challenges of diagnosis and management of tuberculosis and HIV coinfection in resource-limited settings: a case report from Lima, Peru. JIAPAC. 2008; 7 (5): 232-237.
  23. Dhasmana D. J., Dheda K., Ravn P. et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs. 2008; 68: - 191-208.
  24. Meintjes G., Wilkinson R.J., Morroni C. et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associatedimmunereconstitutioninflammatory syndrome. AIDS (London, England). 2010;24(15): 2381-2390.
  25. Michailidis C., Pozniak A. L., Mandalia S. et al. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir. Lher. 2005; 10: 417-422.
  26. Saito W., Pitisuttithum P., Tansuphasawadikul S. et al. Outcome of tuberculosis in advanced HIV-infected patients with antiretroviral therapy. 4th International AIDS Society Conference on HIV Pathogenesis and Lreatment. Australia, Sidney. 2007; MOPEB035.
  27. Lawn S.D., Myer L., Bekker L.G. et al. Luberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-341.
  28. Maruza M., Arraes R., Ximenes A. et al. Lreatment outcome and laboratory confirmation of tuberculosis diagnosis in patients with HIV/AIDS in Recife, Brazil. J. Bras. Pneumol. 2008; 34(6): 394-403.
  29. Schiffer J.Т., Sterling T.R. Liming of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J. AIDS. 2007; 44: 229-234.
  30. Abdool Karim S.S., Naidoo K., Grobler A. et al. Liming of initiation of antiretroviral drugs during tuberculosis therapy. N. Engl. J. Med. 2010; 362: 697-706.
  31. Velasco M., Castillo V., Sanz J. et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J. Acquir. Immune. Defic. Syndr. 2009; 50(2): 148-152.
  32. Chen F., Sethi G., Goldin R. et al. Concurrent granulomatous Pneumocystis cariniiandMycobacteriumxenopi pneumonia: an unusual manifestation of HIV immune reconstitution disease. Lhorax. 2004; 59: 997-999.
  33. Miiller M., Wandel S., Colebunders R. et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect. Dis. 2010; 10: 251-261.
  34. Perfect J.R., Dismukes W.E., Dromer F. et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2010; 50: 291-322.
  35. Makadzange A.T., Ndhlovu C.E., Takarinda K. et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin. Infect. Dis. 2010; 50(11): 1532-1538.
  36. Karavellas M.P., Song M., Macdonald J.C. et al. Long-term posterior and anterior segment complications of immune recovery uveitis associated with cytomegalovirus retinitis. Am. J. Ophthalmol. 2000; 130: 57-64.
  37. Robinson M.R., Reed G., Csaky K.G. et al. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am. J. Ophthalmol. 2000; 130: 49-56.
  38. Domingo P., Torres O.H., Ris J. et al. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am. J. Med. 2001; 110: 605-609.
  39. Martinez E., Gatell J., Moran Y. et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin. Infect. Dis. 1998; 27: 1510-1513.
  40. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents. CDC, MMWR. 2009.
  41. Jimenez-Exposito M.J., Alonso-Villaverde C., Sarda P. et al. Visceral leishmaniasis in HIV-infected patients with non-detec HIV-1 viral load after HAART. AIDS. 1999; 13: 152-153.
  42. Godoy M.C., Silva C.I., Ellis J. et al. Organizing pneumonia as a manifestation of Pneumocystis jiroveci immune reconstitution syndrome in HIV-positive patients: report of 2 cases. J. Thorac. Imaging. 2008; 23: 39-43.
  43. Fox P.A., Boag F.C., Hawkins D.A. et al. Acute porphyria following commencement of indinavir. AIDS. 1999; 13: 622-623.
  44. DeLavaissiere M., Manceron V., Bouree P. et al. Reconstitution inflammatory syndrome related to histoplasmosis, with a hemophagocytic syndrome in HIV infection. J. Infect. 2009; 58(3): 245-247.
  45. Nacher M., Sarazin F., El Guedj M. et al. Increased incidence of disseminated histoplasmosis following highly active antiretroviral therapy initiation. J. Acquir. Immune Defic. Syndr. 2006; 41: 468-470.
  46. Feller L., Anagnostopoulos C., Wood N.H. et al. Human immunodeficiency virus-associated Kaposi sarcoma as an immune reconstitution inflammatory syndrome: a literature review and case report. J. Periodontol. 2008; 79: 362-368.
  47. Leidner R. S., Aboulafia D. M. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS. 2005; 19: 635-644.
  48. Handa S., Bingham J.S. Dermatological immune restoration syndrome: does it exist? J. Eur. Acad. Dermatol. Venerol. 2001; 15: 430-432.
  49. Lehloenya R., Meintjes G. Dermatologic manifestations of the immune reconstitution inflammatory syndrome. Dermatol. Clin. 2006; 24: 549-570.
  50. Couppie P., Abel S., Voinchet H. et al. Immune reconstitution inflammatory syndrome associated with HIV and leprosy. Arch. Dermatol. 2004; 140: 997-1000.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies